Literature DB >> 21155702

Nonadherence in outpatient thromboprophylaxis after major orthopedic surgery: a systematic review.

Thomas Wilke1, Sabrina Müller.   

Abstract

The necessity for extended medication-based thromboprophylaxis after hip/knee-replacement surgery (major orthopedic surgery) has been acknowledged in international guidelines. In this article, we review and critically appraise the literature regarding patients' nonadherence (NA) in outpatient thromboprophylaxis after major orthopedic surgery. We conducted a systematic literature review. All studies published since 1990 and that were found to report research about NA in outpatient thrombosis prophylaxis after major orthopedic surgery were included. Only six relevant contributions could be identified. All these studies dealt with parenteral low-molecular-weight heparins or fondaparinux prophylaxis. The extent of NA (defined as existing when a patient fails to take the prescribed medication on at least 1 day) ranged from 13 to 37%. In one large German survey, patients who were nonadherent missed between 38 and 43% of their outpatient low-molecular-weight heparin injections. Subjective factors can play a role in increasing NA; such factors include a lack of knowledge of or having no fear concerning thrombosis in general and a lack of specific knowledge regarding measures to prevent it, as well as a negative evaluation of injections as the form of therapy application. Waiting times between acute in-hospital treatment and admission to rehabilitation clinics, as well as abstention from stationary rehabilitation programs, form objective adherence barriers. Therefore, NA is a phenomenon influenced by subjective patient-related factors as well as objective, care-provision structural factors. Current trends in patient care (e.g., shorter hospital stays and lengthened ambulant care) are likely to increase both the number of nonadherent patients and the extent of NA, if the current state of knowledge proves an accurate predictor of the future. At present, it appears that between one and two of every five patients are not adherent when parenteral prophylaxis is used. Whether or not new oral anticoagulation alternatives will be capable of improving the situation remains open for future research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21155702     DOI: 10.1586/erp.10.77

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  13 in total

1.  Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  High Risk of Symptomatic Venous Thromboembolism After Surgery for Spine Metastatic Bone Lesions: A Retrospective Study.

Authors:  Olivier Q Groot; Paul T Ogink; Nuno Rei Paulino Pereira; Marco L Ferrone; Mitchell B Harris; Santiago A Lozano-Calderon; Andrew J Schoenfeld; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

Review 3.  Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

4.  High Risk of Venous Thromboembolism After Surgery for Long Bone Metastases: A Retrospective Study of 682 Patients.

Authors:  Olivier Q Groot; Paul T Ogink; Stein J Janssen; Nuno Rui Paulino Pereira; Santiago Lozano-Calderon; Kevin Raskin; Francis Hornicek; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2018-10       Impact factor: 4.176

5.  Patient Adherence and Experience with Extended Use of Prophylactic Low-Molecular-Weight Heparin Following Pancreas and Liver Resection.

Authors:  Madeline Lemke; Kaitlyn Beyfuss; Julie Hallet; Natalie G Coburn; Calvin H L Law; Paul J Karanicolas
Journal:  J Gastrointest Surg       Date:  2016-09-29       Impact factor: 3.452

6.  Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer.

Authors:  M Farzan Rashid; Terri L Jackson; Jheanell A Morgan; Franklin A Dwyer; Beth A Schrope; John A Chabot; Michael D Kluger
Journal:  J Gastrointest Surg       Date:  2018-09-05       Impact factor: 3.452

7.  Patients' perceptions and experiences of the prevention of hospital-acquired thrombosis: a qualitative study.

Authors:  Patricia N Apenteng; David Fitzmaurice; Ian Litchfield; Sian Harrison; Carl Heneghan; Alison Ward; Sheila Greenfield
Journal:  BMJ Open       Date:  2016-12-13       Impact factor: 2.692

8.  Does venous thromboembolism prophylaxis affect the risk of venous thromboembolism and adverse events following primary hip and knee replacement? A retrospective cohort study.

Authors:  F Todd; D Yeomans; M R Whitehouse; G S Matharu
Journal:  J Orthop       Date:  2021-05-25

Review 9.  Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.

Authors:  Toby Trujillo; Paul P Dobesh
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

10.  Prevention of hospital-acquired thrombosis from a primary care perspective: a qualitative study.

Authors:  Ian Litchfield; David Fitzmaurice; Patricia Apenteng; Sian Harrison; Carl Heneghan; Alison Ward; Sheila Greenfield
Journal:  Br J Gen Pract       Date:  2016-06-06       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.